Mostrar el registro sencillo del ítem
| dc.contributor.author | Serrano-Villar, Sergio | |
| dc.contributor.author | López-Huertas, María-Rosa | |
| dc.contributor.author | Jiménez, Daniel | |
| dc.contributor.author | Galera, Carlos | |
| dc.contributor.author | Martínez-Sanz, Javier | |
| dc.contributor.author | Moreno, Elena | |
| dc.contributor.author | Muriel, Alfonso | |
| dc.contributor.author | Gutiérrez, Félix | |
| dc.contributor.author | Busca, Carmen | |
| dc.contributor.author | Portilla, Joaquín | |
| dc.contributor.author | Bisbal, Otilia | |
| dc.contributor.author | Iribarren, José-Antonio | |
| dc.contributor.author | Tejerina, Francisco | |
| dc.contributor.author | de-los-Santos, Ignacio | |
| dc.contributor.author | Moreno, Santiago | |
| dc.date.accessioned | 2025-11-21T08:43:59Z | |
| dc.date.available | 2025-11-21T08:43:59Z | |
| dc.date.issued | 2022-03 | |
| dc.identifier.citation | Serrano-Villar S, López-Huertas MR, Jiménez D, Galera C, Martínez-Sanz J, Moreno E, et al. Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens. Front Immunol. 14 de marzo de 2022;13:848630. | |
| dc.identifier.issn | 1664-3224 | |
| dc.identifier.uri | https://sms.carm.es/ricsmur/handle/123456789/21919 | |
| dc.description.abstract | BACKGROUND: Because inflammation is associated with mortality and has been linked to HIV transcription in lymphoid tissues during ART, it is necessary to address the long-term effects of switching 3-drug (3DR) to 2-drug regimens (2DR) on inflammation. METHODS: Nested study in the Spanish AIDS Research Network. We selected PWH ART-naive initiating 3DR who achieved viral suppression in the first 48 weeks and either remained on 3DR or switched to 2DR (3TC+bPI; 3TC+DTG; DTG+RPV). We assessed the trajectories on inflammatory markers during ART using multivariate piecewise mixed models. RESULTS: We analyzed 619 plasma samples from 148 patients (3DR, N=90; 2DR, N=58), the median follow-up was 4.6 (IQR 3.2-6.2) years. There were no significant differences in baseline characteristics between groups. After adjusting for potential confounders, patients with 3DR experienced a slow decline of IL6, hs-CRP, sCD14, sCD163, and D-dimer over time. In contrast, compared to 3DR, switching to 2DR was associated with increases in IL-6 (p=0.001), hs-CRP (p=0.003), and D-dimer (p=0.001) after year 3 from virologic suppression. 2DR was associated with a higher risk of hs-CRP quartile increase (aOR 3.3, 95%CI 1.1-10) and D-dimer quartile increase (aOR 3.7, 95%CI 1.1-13). The adjusted biomarker trajectories did not reveal a distinct pattern according to the type of 2DR used (bPI vs DTG). CONCLUSIONS: In this study in virally suppressed individuals, maintaining 3DR was associated with a more favorable long-term inflammatory profile than switching to 2DR. The potential clinical implications of these findings on the development of non-AIDS events deserve further investigation. | |
| dc.language.iso | eng | |
| dc.publisher | FRONTIERS MEDIA SA | |
| dc.rights | Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/es/ | * |
| dc.subject.mesh | Anti-HIV Agents/therapeutic use | |
| dc.subject.mesh | Anti-Retroviral Agents/therapeutic use | |
| dc.subject.mesh | Biomarkers | |
| dc.subject.mesh | C-Reactive Protein/therapeutic use | |
| dc.subject.mesh | HIV Infections/drug therapy | |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Inflammation/drug therapy | |
| dc.subject.mesh | Lamivudine | |
| dc.title | Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens | |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.pmid | 35359950 | |
| dc.relation.publisherversion | https://www.frontiersin.org/articles/10.3389/fimmu.2022.848630/full | |
| dc.identifier.doi | 10.3389/fimmu.2022.848630 | |
| dc.journal.title | Frontiers in Immunology |